Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cPLT-002
- Development stage
- Preclinical
- Lead developer
- Suzhou Xueji Biotechnology
- Modality
- Cell Therapies
01
Overview
cPLT-002 is an undisclosed preclinical-stage candidate being developed by Suzhou Xueji Biotechnology (also known as HemaCell Therapeutics) for aging-related indications. It is part of the company's aging-related pipeline, which leverages its proprietary stem cell-derived platelet regeneration technology. Suzhou Xueji Biotechnology is a pioneer in the in vitro regeneration of platelets from stem cells, aiming to address blood supply shortages and develop novel therapeutics for transfusion, oncology, and anti-aging applications. cPLT-002 is planned for dual filing in both China and the United States.
Beyond the preview
Go deeper on cPLT-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cPLT-002.